Published in:
Open Access
01-05-2014 | Oral presentation
Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase 1 production
Authors:
Giusy Gentilcore, Coaña Pico de Yago, Isabel Poschke, Yumeng Mao, Maria Nyström, Johan Hansson, Giuseppe V Masucci, Rolf Kiessling
Published in:
Journal of Translational Medicine
|
Special Issue 1/2014
Login to get access
Excerpt
Ipilimumab (Yervoy) is a fully human antibody that blocks CTLA-4 and has proven to extend overall survival in patients with unresectable stage III or stage IV melanoma [
1]. Immune related adverse effects (IRAE) are frequent and can be severe but are reversible with early diagnosis and can be managed with corticosteroid therapy [
2]. Most of the recently published immune monitoring studies focus mainly on the effect that ipilimumab has on T cell populations [
3]. To date, little information is available on the possible impact that ipilimumab treatment may have on MDSC populations and their suppressive mechanisms [
4]. In order to evaluate these effects, we conducted an in-depth immune monitoring study centered on peripheral blood MDSC populations as well as T cells in advanced melanoma patients undergoing treatment with ipilimumab. …
